MYHAEVYN
DEAD

Serial Number

97774125

Owner

CSL BEHRING GMBH

Attorney

Scott D. Woldow

Filing Date

Jan 31, 2023

Add to watchlist:

No watchlists yet
View on USPTO

MYHAEVYN Trademark

Serial Number: 97774125

MYHAEVYN is a trademark filed by CSL BEHRING GMBH on January 31, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

CSL BEHRING GMBH (101 trademarks)

EMIL-VON-BEHRING STRASSE 76
MARBURG (LAHN) , DE

Entity Type: 16

Trademark Details

Filing Date

January 31, 2023

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; antibodies

Filing History

ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT
Jun 21, 2023 MAB1
ABANDONMENT - EXPRESS MAILED
Jun 21, 2023 ABN1
TEAS EXPRESS ABANDONMENT RECEIVED
Jun 20, 2023 EXAR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 17, 2023 NWOS
NEW APPLICATION ENTERED
Feb 3, 2023 NWAP